Celgene Overview
- Founded
- 1986
- Status
- Acquired/Merged
- Employees
- 5,348
- Latest Deal Type
- M&A
- Latest Deal Amount
- $80.3B
Celgene General Information
Description
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
Contact Information
Website
www.celgene.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Office
- 86 Morris Avenue
- Summit, NJ 07901
- United States
+1 (908) 000-0000
Celgene Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 20-Nov-2019 | $80.3B | 000.00 | 000.00 | Completed | Profitable |
| 3. PIPE | 000.00 | Completed | Profitable | |||
| 2. IPO | 28-Jul-1987 | $12.7M | $12.7M | Completed | Generating Revenue | |
| 1. Early Stage VC | 01-Jan-1986 | Completed | Generating Revenue |
Celgene Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and i
Biotechnology
Summit, NJ
5,348
As of 2020
000.00
00.00
0000-00-00
000000&0
000.00
0000000
, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
0000 000000000
Bothell, WA
0000
As of 0000
00.000
000000000
00.000
00000000
quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
000000000000000
Tarrytown, NY
0000
As of 0000
00000
00000000000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialCelgene Competitors (20)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Seattle Genetics | Formerly VC-backed | Bothell, WA | 0000 | 00.000 | 000000000 | 00.000 |
| 000000000 00000000 | Formerly VC-backed | Tarrytown, NY | 0000 | 00000 | 00000000000 | 00000 |
| 000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000&0 | |
| 000000000 | Formerly VC-backed | Exton, PA | 000 | 0000 | 000000&0 | 0000 |
| 000000 | Formerly VC-backed | Cambridge, MA | 0000 | 000.00 | 00000000000 | 000.00 |
Celgene Executive Team (63)
Celgene Board Members (28)
| Name | Representing | Role | Since |
|---|---|---|---|
| Carrie Cox | Self | Board Member | 000 0000 |
| Ernest Mario Ph.D | Self | Board Member | 000 0000 |
| Gilla Kaplan | Self | Board Member | 000 0000 |
| Hans Bishop | Self | Board Member | 000 0000 |
| James Loughlin | Self | Board Member | 000 0000 |
Celgene Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialCelgene Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Asseily Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| BB Biotech | Asset Manager | Minority | 000 0000 | 000000 0 | |
| CHL Medical Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Edelson Technology Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Ridgeback Capital | Other | Minority | 000 0000 | 000000 0 |
Celgene Investments & Acquisitions (126)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000 0000000000 | 07-Jan-2020 | 00000 00000 00 | 0000 | Decision/Risk Analysis | |
| 0000000 | 20-Dec-2019 | 00000 00000 00 | 000.00 | Drug Discovery | |
| 000000 00000000000 | 15-Oct-2019 | 00000 00000 00 | 000.00 | Drug Discovery | 00000 000000000 |
| 0000000 | 11-Sep-2019 | 00000 00000 00 | 000.00 | Drug Discovery | |
| RAPT Therapeutics | 18-Jun-2019 | Later Stage VC | 0000 | Drug Discovery |
Celgene Subsidiaries (5)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| EngMab | Biotechnology | Pfaffikon, Switzerland | 2013 |
| 000000000 00000000 | Therapeutic Devices | San Francisco, CA | 0000 |
| 00000000 000000000 | Drug Discovery | Boston, MA | 0000 |
| 00000000 000000000 | Pharmaceuticals | Summit, NJ | 0000 |
| 0000000000000 | Diagnostic Equipment | Rockville, MD | 0000 |
Celgene Exits (53)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000 | 20-Dec-2019 | 00000 00000 00 | 000.00 | Completed |
|
| 0000 000000000000 | 18-Jun-2019 | 00000 00000 00 | 0000 | Completed |
|
| 00000000000 | 13-Mar-2019 | 00000 00000 00 | 0000 | Completed |
|
| 0000000000 0000000 | 05-Mar-2019 | 00000 00000 00 | 000.00 | Completed |
|
| Silverback Therapeutics | 19-Sep-2018 | Early Stage VC | 000.00 | Completed |
|